Telomeres and telomerases as drug targets

Current Opinion in Pharmacology

Volumn 2, Issue 4, 2002, Pages 415-423

  Rezler, Evonne M ^a   Bearss, David J ^b   Hurley, Laurence H ^a,b,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c University of Arizona   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE DERIVATIVE; ANILINE DERIVATIVE; ANTISENSE OLIGONUCLEOTIDE; CYTOTOXIC AGENT; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); ENZYME INHIBITOR; HELICASE; MESSENGER RNA; PHENOXAZINE DERIVATIVE; RIBOZYME; RNA DIRECTED DNA POLYMERASE; TELOMERASE; TELOMERASE INHIBITOR; TRIAZINE DERIVATIVE;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA STRUCTURE; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; ONCOGENE C MYC; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SYNTHESIS; TELOMERE; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; HUMAN; METABOLISM; METHODOLOGY; REVIEW;

ANIMALS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; TELOMERASE; TELOMERE;

EID: 0036667390     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00182-0     Document Type: Review

References (78)

1. Telomeres shorten during aging of human fibroblasts
2. Telomeres and aging
3. A tandemly repeated sequence at the termini of extrachromosomal ribosomal RNA genes in Tetrahymena
4. Human telomeres contain at least three types of G-rich repeats distributed non-randomly
5. Structure and variability of human chromosome ends
6. n, present at the telomeres of human chromosomes
7. p53 binds telomeric single strand overhangs and t-loop junction in vitro
8. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening
9. Normal human chromosomes have long G-rich telomeric overhangs at one end
10. Telomere maintenance mechanisms and cellular immortalization
11. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity
12. TRF2 protects human telomeres from end-to-end fusions
13. For better or worse? Telomerase inhibition and cancer
14. Telomere reduction in human colorectal carcinoma with aging
15. Telomere shortening in renal cell carcinoma
16. Origin of concatemeric T7 DNA
17. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon
18. Evidence for a new step in telomere maintenance
19. Purification of Tetrahymena telomerase and cloning of genes encoding the two protein components of the enzyme
20. Telomerase catalytic subunit homologs from fission yeast and human
21. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization
22. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types
23. Human telomerase contains evolutionarily conserved catalytic and structural subunits
24. Functional requirements of p23 and Hsp 90 in telomerase complexes
25. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
26. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase
27. Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells
28. Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture
29. Mechanism of telomerase induction during T cell activation
30. Telomerase is controlled by protein kinase Cα in human breast cancer cells
31. Sp1 cooperates with c-myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT)
32. Myc activates telomerase
33. Telomerase reverse transcriptase gene is a direct target of c-myc but is not functionally equivalent in cellular transformation
34. The cationic porphyrin TMPyP4 downregulates c-MYC and hTERT expression and inhibits tumor growth in vivo
35. Inhibition of human telomerase activity by peptide nucleic acids
36. Cellular delivery of peptide nucleic acids and inhibition of human telomerase
37. Locked nucleic acid (LNA): Fine-tuning the recognition of DNA and RNA
38. Telomerase inhibitors-oligonucleotide phosphoramidates as potential therapeutic agents
39. Inhibition of human telomerase by 2′-O-methyl-RNA
40. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death
41. Inhibition of telomerase by 2′-O-(2-methoxyethyl) RNA oligomers: Effect of length, phosphorothioate substitution and time inside cells
42. Telomerase inhibition, oligonucleotides, and clinical trials
43. Telomerase inhibitors for the treatment of cancer: The current perspective
44. Natural and pharmacological regulation of telomerase
45. 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells
46. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component
47. Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA
48. Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas
49. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells
50. Hammerhead ribozymes to modulate telomerase activity of endometrial carcinoma cells
51. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells
52. Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells
53. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate
54. A highly selective telomerase inhibitor limiting human cancer cell proliferation
55. Inhibition of human telomerase by 7-deaza-2′-deoxyguanosine nucleoside triphosphate analogs: Potent inhibition by 6-thio-7-deaza-2′-deoxyguanosine 5′-triphosphate
56. Interaction of deoxyguanosine nucleotide analogs with human telomerase
57. Inhibition of telomerase by G-quartet DNA structures
58. 3] G-tetraplex
59. Inhibition of human telomerase by a G-quadruplex-interactive compound
60. Telomerase assay using biotinylated-primer extension and magnetic separation of the products
61. A DNA polymerase stop assay for screening for G-quadruplex-interactive compounds
62. The development of telomerase inhibitors: The G-quartet approach
63. Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors
64. Ethidium derivatives bind to G-quartets, inhibit telomerase and act as fluorescent probes for quadruplexes
65. Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes
66. Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands
67. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex
68. Design and synthesis of fluoroquinophenoxazines that interact with human telomeric G-quadruplexes and their biological effects
69. Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos
70. Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus
71. G-quadruplex DNA: A target for drug design
72. G-quadruplex DNA: A potential target for anticancer drug design
73. G-quadruplex DNA as a target for drug design
74. DNA and its associated processes as targets for cancer therapy
75. Selective interactions of cationic porphyrins with G-quadruplex structures
76. Inhibition of unwinding of G-quadruplex structures by Sgs1 helicase in the presence of N,N'-bis[2-(1-piperidino)ethyl]-3,4,9,10-perylenetetracarboxylic diimide, a G-quadruplex-interactive ligand
77. Sequence and structural selectivity of nucleic acid binding ligands
78. Telomere maintenance mechanisms as a target for drug development